Zepound—an Eli Lilly-produced drug that has become a popular alternative to other weight loss drugs such as Wegovy and Ozempic—is facing a shortage in the U. S. of some of its doses because of the growing demand for the drug, according to a warning from the Food and Drug Administration issued Wednesday. Zepbound is an injection used to help overweight people lose weight by reducing appetite and food intake. The drug helps people who are obese or overweight and facing weight-related medical issues such as type 2 diabetes or high blood pressure. Last year, Zepbound received FDA approval and became the latest weight loss drug to be available in U. S. pharmacies alongside Ozempic and Wegovy. While those drugs were created to deal with diabetes, they’ve become increasingly prescribed to treat obesity. While Wegovy and Zepbound have been approved as a weight loss treatment, Ozempic has not. Before Zepbound was FDA approved, the active ingredient in the medication, tirzepatide, was approved by the FDA and marketed by Eli Lilly as Mounjaro, a weekly diabetes drug injection used to help control blood sugar.22.5%. That’s the percentage of weight lost by participants in clinical trials done ahead of Zepbound’s FDA approval. In February, a study published by the American Heart Association’s journal Hypertension found that overweight patients taking tirzepatide saw significant reductions in their blood pressure, indicating patients taking Zepbound could see more than one positive side effect.
All data is taken from the source: http://forbes.com
Article Link: https://www.forbes.com/sites/anafaguy/2024/04/03/why-theres-limited-supply-of-the-weight-loss-drug-zepbound/
#newsnbc #newstodayupdate #newstodayheadlines #newsworldfox #newstodaymsnbc #newstodaybbc #